Andrew Moreno

DocwireNews

A phase II trial evaluated venetoclax plus cladribine, idarubicin, and cytarabine as first-line induction therapy for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The findings were presented at the 66th American Society of Hematology Annual Meeting &amp; Exposition in San Diego, California.
Lead author Ian Bouligny, MD, of the University of Texas MD Anderson Cancer Center, Houston, wrote that the combination is “a highly effective regimen, producing deep and durable remissions in patients with newly diagnosed AML.”
The study cohort included 95 patients aged 65 years or younger with a new diagnosis of disease; 90% had AML, 7% had high-risk MDS, and 3% had mixed phenotype acute leukemia. The median age at diagnosis was 49 years among patients with AML and 46 years among patients with MDS. The most common mutation in the total cohort was in NPM1 at 31%.
Patients received cladribine 5 mg/m2 and cytarabine 1 to 1.5 mg/m2 on cycle days 1 through 5, idarubicin 8 to 10 mg/m2 on days 1 through 3, and venetoclax 400 mg on days 2 through 8. The total cohort received a median of two cycles of therapy.
The cohort had a median follow-up of 2.5 years, and the overall response rate (ORR) was 95%. Eighty-four percent of the cohort achieved complete response (CR), and 8% achieved CR with incomplete hematologic recovery.
The ORR for patients with AML classified as favorable, intermediate, and adverse risk was 100%, 97%, and 89%, respectively. Among patients with AML who achieved a composite CR in the study, 82% achieved measurable residual disease–negative CR as determined by multiparameter flow cytometry. One patient with AML had a partial response. One patient with MDS had hematologic improvement.
Median overall survival (OS) was not reached in the study. For patients with AML, the calculated probability of OS was 85% at one year, 73% at two years, and 71% at four years, and relapse-free survival (RFS) was 78% at one year and 75% at two years. Patients with MDS had a 100% probability of OS at one and two years, and an RFS of 86% at one and two years.
“High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic [stem cell transplant (SCT)]. Low relapse rates following SCT translate to an estimated overall survival of 71% at 4 years in patients with newly diagnosed AML,” Dr. Bouligny elaborated.
Among patients with AML in the study, all experienced grade 3 or higher anemia, leukopenia, neutropenia, and thrombocytopenia. There also occurred grade 3 or higher bacteremia in 28% of these patients, pneumonia in 22%, and colitis in 14%. There was also grade 3 or higher alanine transaminase elevation in 19% of these patients, aspartate aminotransferase elevation in 7%, and bilirubin elevation in 7%.
The 30- and 60-day mortality rate for the total cohort was 1% and 2%, respectively.
Reference
Bouligny IM, Kantarjian HM, Yilmaz M, et al. A phase II trial of venetoclax in combination with cladribine, idarubicin, and cytarabine in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Abstract #734. Presented at the 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.

Cecilia Brown

FDA Issues Complete Response Letter for Subcutaneous Amivantamab in NSCLC

Non-Small Cell Lung Cancer

IWG 2023, 2006 MDS Criteria Assessments of Ivosidenib for mIDH1 Disease Compared

ASH 2024

Venetoclax, Cladribine, Idarubicin, Cytarabine Regimen Evaluated in AML, High-Risk MDS

Latest News

The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe